Dexcom Inc at William Blair Growth Stock Conference Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Margaret Kaczor Andrew - William Blair - Analyst : Well, number one, I was trying to convince you it's actually launched this Stelo at this conference was unsuccessful and also trying to say everyone in this audience should get a free Stelo similarly unsuccessful that you're working on margins so I understand why. Now all that said, obviously, the timing was new news for us. So I do appreciate that. I think most people in the audience know how bullish we are at least about this as an opportunity. And frankly, the more research we do have as bullish as I am and it feels like the market's trying to push us into something more bullets. I know you appreciate that me raising expectations You're welcome app. But you know, maybe ground us a little bit in terms of the non-insulin use that we've seen today. And is that a population that's similar to the Stelo population? Or will you continue to expand beyond usage? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 05, 2024 / 8:20PM, DXCM.OQ - Dexcom Inc at William Blair Growth Stock Conference

Question: Margaret Kaczor Andrew - William Blair - Analyst : And so there will be some shorter questions as well that have certainly been asked to ask you, but I can't help but keep going on this topic. And so as we kind of think about at the initial Stelo launch you talked talk about it being unconstrained, which frankly normally they do a limited market release. And even in this scenario, that's probably what I would have expected because you do want to understand how people react to the software that you will put out. And so maybe walk us through why your confidence around that as a point.

Question: Margaret Kaczor Andrew - William Blair - Analyst : One of the things that's been interesting to me and I can point out to folks is you don't get to [6 to 800,000] non-insulin users overnight. And there's actually quite a bit of experience within this market beyond whether yourselves your competitor. And so maybe one of the pushbacks as churn is going to be too high. This is going to be a fad and you referenced software that theoretically should even improve that churn. But can you speak anything to that means?

Question: Margaret Kaczor Andrew - William Blair - Analyst : Maybe let's fast-forward to today second quarter, and you guys have referenced this since the beginning of the year, you're doing a big sales force hire. You're trying to integrate that in. Now my perspective is if you're going to have big launch, I don't need to have a commercial structure that supports that. But the other flip side would be there something else going on. So maybe walk us through why now from a commercial sale structure change and what are the reasons comments you had on that?

Question: Margaret Kaczor Andrew - William Blair - Analyst : And so and maybe just to wrap all of that up, as we think about your guidance, both for the second quarter, you did have some comments. Maybe you're not specific as much as for guidance for Q2, but walk us through what you said on Q2, full year and what was contemplated in that? And then the third piece, how does that compare to the [Stelo] estimates and whether you're comfortable with it?

Question: Margaret Kaczor Andrew - William Blair - Analyst : Perfect. With that, we'll wrap it up here and then we'll have the breakout up in their. Thank you.